Skip to main content

Table 1 Baseline demographic and clinical patient characteristics

From: Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial

 

Placebo

Imatinib

n

33

33

Admission characteristics

  

Age in years, mean (SD)

62 (11.4)

63 (9.3)

Male sex, n (%)

19 (58)

19 (58)

BMI in kg/m2, median [IQR]

30 [28, 35]

28 [25, 32]

ARDS classification (Berlin criteria)

  

 Severe, n (%)

6 (18)

7 (21)

 Moderate, n (%)

27 (82)

26 (79)

SOFA score, median [IQR]

8 [7.0, 8.0]

7 [6.8, 9.0]

Charlson comorbidity score, median [IQR]

2 [1, 4]

2 [1, 4]

Fluid balance in liters, median [IQR]

0.46 (1.01)

0.12 (1.3)

QTc in msec, mean (SD)

451.0 (31.6)

447.8 (29.6)

IL-6 receptor inhibitors*, n (%)

30 (91)

30 (91)

Dexamethasone, n (%)

31 (94)

30 (91)

Completed 10-day dexamethasone treatment before ICU admission, n (%)

2 (6)

3 (9)

Vaccinated, n (%)

  

 No

19 (58)

14 (42)

 Yes

6 (18)

11 (33)

 Unknown

8 (24)

8 (24)

Time from symptoms until intubation in days, median [IQR]

11 [8, 15]

12 [9, 13]

Comorbidities†

  

COPD, n (%)

1 (3)

0 (0)

Heart failure, n (%)

0 (0)

0 (0)

Renal failure, n (%)

2 (6)

2 (6)

Myocardial infarction, n (%)

1 (3)

2 (6)

Ventilation and gas exchange

  

TV/PBW in ml/kg, median [IQR]

6.2 [5.8, 7.2]

6.2 [5.6, 7.5]

PaO2/FiO2 in mmHg, mean (SD)

138 (35.8)

130 (34.9)

PEEP in cmH2O, mean (SD)

11.2 (2.3)

10.6 (2.8)

Laboratory measurements

  

Hemoglobin in g/dL, median [IQR]

13.5 [13.1, 13.9]

13.1 [12.3, 13.9]

Leucocytes × 109/L, median [IQR]

10.8 [7.7, 14.6]

10.1 [8.4, 16.2]

Thrombocytes × 109/L, median [IQR]

267 [223, 348]

265 [227, 367]

D-dimer in mg/L, median [IQR]

1.7 [0.9, 4.0]

3.5 [1.3, 12.7]

Creatinine in micromol/L, median [IQR]

90 [65, 108]

84 [71, 121]

NTproBNP in pg/ml, median [IQR]

140 [62, 424]

169 [74, 471]

AST in U/L, median [IQR]

56 [48, 88]

53 [38, 77]

ALT in U/L, median [IQR]

57 [40, 114]

41 [27, 62]

PiCCO measurements

  

EVLW in ml, median [IQR]

1039.0 [884.5, 1185.8]

1026.5 [849.3, 1363.5]

EVLWi in ml/kg, median [IQR]

15.2 [12.8, 18.5]

15.3 [13.7, 19.5]

PVPi, median [IQR]

3.1 [2.6, 3.9]

3.7 [2.8, 4.7]

  1. ALT alanine transaminase; ARDS Acute Respiratory Distress Syndrome; AST aspartate transaminase; BMI Body Mass Index; COPD chronic obstructive pulmonary disease; COVID-19 Coronavirus disease 2019; EVLW(i) extravascular lung water (index); FiO2 fraction of inspired oxygen; ICU intensive care unit; IL-6 interleukin-6; IQR interquartile range; NTproBNP N-terminal prohormone brain natriuretic peptide; PaO2 partial pressure of oxygen; PCR Polymerase chain reaction; PEEP positive end-expiratory pressure; PiCCO pulse contour cardiac output; PVPi pulmonary vascular permeability index. QTc corrected QT interval time; SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2; SD standard deviation; SOFA Sequential Organ Failure Assessment; TV/PBW tidal volume indexed to predicted body weight; PVPi pulmonary vascular permeability index
  2. *Tocilizumab (8 mg/kg single intravenous administration) or sarilumab (400 mg single intravenous administration) administered upon Intensive Care Unit admission
  3. †Known history of the disease at the moment of randomization
Back to article page

Critical Care

ISSN: 1364-8535